- Home
- NRDS vs SGP Comparison
NRDS vs SGP Comparison
Compare NRDS & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRDS | SGP |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 720.4M | 650.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRDS | SGP |
|---|---|---|
| Price | $9.97 | $25.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $15.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 616.1K | 91.1K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.42 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $836,600,000.00 | N/A |
| Revenue This Year | $10.13 | N/A |
| Revenue Next Year | $7.11 | N/A |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $7.33 | $17.06 |
| 52 Week High | $16.24 | $30.56 |
Technical Indicators
Market Signals| Indicator | NRDS | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 68.69 |
| Support Level | $8.65 | $20.95 |
| Resistance Level | $9.75 | $25.83 |
| Average True Range (ATR) | 0.31 | 1.34 |
| MACD | -0.05 | 0.38 |
| Stochastic Oscillator | 17.59 | 95.56 |
Price Performance
Historical ComparisonAbout NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.